What does Larotrectinib (Vitrakvi) do in plain English—and how does it work inside your body?
Larotrectinib is an FDA-regulated Kinase Inhibitor (RxNorm RxCUI RXN-71777390-2238). Mechanistically, Upon oral-route administration of 25 mg/1 Capsule and 20 mg/mL Solution, Concentrate, Larotrectinib (manufactured/labeled by Loxo Oncology, Inc.; NDC 71777-390, 50419-392) engages kinase inhibitor biochemical pathways to achieve steady-state therapeutic response balanced against organ-specific metabolic elimination. [1][2].
When your doctor writes a prescription for Larotrectinib (RxNorm RxCUI RXN-71777390-2238, also dispensed under brand names including Vitrakvi), the goal is to target the root physiological pathway driving your condition rather than just masking surface symptoms [1]. According to the official FDA DailyMed package insert, Upon oral-route administration of 25 mg/1 Capsule and 20 mg/mL Solution, Concentrate, Larotrectinib (manufactured/labeled by Loxo Oncology, Inc.; NDC 71777-390, 50419-392) engages kinase inhibitor biochemical pathways to achieve steady-state therapeutic response balanced against organ-specific metabolic elimination. [2].
Across real-world patient logs on dotMD (79% positive worth-it rating), patients do best when they understand both what the medication is doing on day 1 and how long it takes to reach steady-state protection [3].
Check the imprint code on your Larotrectinib tablet bottle and confirm with your pharmacist that it matches your prescribed strength (25 mg/1 Capsule, 20 mg/mL Solution, Concentrate, 100 mg/1 Capsule, 20 mg/mL Solution).